PREDICTIVE ONCOLOGY INC (POAI) Stock News
NASDAQ:POAI - Nasdaq - US74039M3097 - Common Stock - Currency: USD
POAI Latest News, Press Relases and Analysis
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapies...
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapies
Mentions: LH
Court Denies Renovaro Motion for an Expedited Trial in July
Court Denies Renovaro Motion for an Expedited Trial in July
PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following...
What's Going On With Predictive Oncology Shares Tuesday?
Predictive Oncology shares are trading higher on Tuesday after the company announced it developed predictive models to target various cancer types.
Predictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans Bullish
Renovaro said the Delaware Court of Chancery had approved an expedited trial schedule for the lawsuit it filed to enforce a binding merger agreement with Predictive Oncology.
Mentions: RENB
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
Mentions: RENB
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
Mentions: RENB
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples...
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples
Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health"
Latest developments expand Predictive’s AI-driven drug discovery platform to include biomarker discovery and drug repurposing With the global biomarker...
Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health"
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update...
Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates
Senseonics (SENS) delivered earnings and revenue surprises of 0% and 16.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: SENS
Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs
Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
Mentions: RENB
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
Company continues to progress toward the signing of a definitive merger agreement with Renovaro
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
Company continues to progress toward the signing of a definitive merger agreement with Renovaro...
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan ...
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
Deal positions STREAMWAY® Systems with an established market leader to drive accelerating growth Transaction allows Predictive Oncology to be highly...
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology
Mentions: RENB
Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences
Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business...
Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences
Mentions: RENB